Vendor qualification in pain management and physical medicine
Pain management practices and physical medicine and rehabilitation groups frequently handle a higher volume of injectable and biologic products than a general practice, so vendor qualification tends to run through a practice's compliance or office-management staff rather than an individual clinician.
That review typically covers whether the distributor restricts sales to licensed professionals, whether lot-specific documentation is available before an order ships, and how returns or product issues are handled.
Stockton
NPPES registry listings, primary taxonomy, retrieved 2026-10-27
37- Pain Medicine
- 22
- Physical Medicine & Rehabilitation
- 15
Documentation to request before adding a new biologic
These records form the baseline most practices request. Precision Biologics makes them available to verified accounts and can walk a practice's physicians through what each document covers.
- Certificate of analysis for the specific lot
- Donor eligibility summary describing donor screening
- Lot release record confirming sterility testing and release criteria were met
Shipping and storage across the West
Cryopreserved products are held at -80 degrees C and move overnight on dry ice in validated containers. Practices in the West region should plan their receiving schedule around the ship date rather than treating delivery as incidental, since a delay in moving product into storage can affect the lot.
Lyophilized formats are shelf-stable and do not require cryogenic storage, which can simplify receiving for practices that prefer not to manage a cold-chain workflow.
Confirming regulatory posture before ordering
Pain management and physical medicine practices in California should confirm current requirements with the California medical board and with their own counsel, particularly for any product marketed as an extracellular vesicle or exosome product, since FDA has stated there are no FDA-approved exosome products and these are generally regulated as biologic drugs. Precision Biologics does not advise on clinical use, dosing, or procedures, and account setup requires NPI verification.
FDA has stated there are no FDA-approved exosome products. Exosome products are generally regulated as biologic drugs under section 351 of the Public Health Service Act, not as 361 HCT/Ps. Purchase and clinical use decisions belong to the physician with their own regulatory counsel.
These products are not FDA approved or licensed for any disease or condition. Information is for licensed healthcare professionals and is not medical or legal advice.
Frequently asked questions
Can a pain management practice in Stockton open a direct account?+
Yes. Pain management and physical medicine practices can open a verified account once their NPI number and licensure are confirmed. Pricing and lot documentation are shared with verified accounts directly.
Are exosome products treated the same as Wharton's jelly products for regulatory purposes?+
No. FDA has stated there are no FDA-approved exosome products and generally regulates them as biologic drugs, while Wharton's jelly products are offered under the supplier's HCT/P framework. Whether a specific intended use qualifies under 21 CFR 1271.10 is a determination for the practice and its counsel.
What should a Stockton pain management clinic plan for when receiving a cold-chain shipment?+
Confirm who will be on-site to receive the shipment on the expected delivery date and move cryopreserved product directly into -80 degree C storage, since it arrives on dry ice in a validated container.